Oneview Healthcare PLC Chess Depository Interests repr 1 (AU:ONE)
ASX:ONE
Want to see AU:ONE full AI Analyst Report?
Top Page
Oneview Healthcare Chess Depository Interests repr 1
(Sydney:ONE)
Select Model
Select Model
Rating:48Neutral
Price Target:
AU$0.17
▼(-33.46% Downside)
Action:Reiterated
Date:03/21/26
The score is held back primarily by weak financial performance (ongoing large losses and cash burn) and bearish technical trend (below key moving averages with negative MACD). This is partially offset by constructive earnings-call commentary pointing to sustained growth, cost reductions, and expanding commercial access (Baxter/GPO), while valuation support is limited due to loss-making results and no dividend.
Positive Factors
Sustained revenue and deployment momentum
Consistent top‑line expansion (21% reported, >25% constant currency) and faster H2 deployments support a durable growth base. Growing live endpoints and ARR provide recurring revenue that, if sustained, enables operating leverage and scaled product investment over 2–6 months and beyond.
Negative Factors
Persistent negative operating and free cash flow
Consistent cash burn means the business depends on external financing to fund operations and growth. With modest year‑end cash and cash decline aligned to losses, runway and dilution risk are structural concerns until operations generate sustained positive cash flow.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained revenue and deployment momentum
Consistent top‑line expansion (21% reported, >25% constant currency) and faster H2 deployments support a durable growth base. Growing live endpoints and ARR provide recurring revenue that, if sustained, enables operating leverage and scaled product investment over 2–6 months and beyond.
Read all positive factors
Oneview Healthcare Chess Depository Interests repr 1 (ONE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$138.10M
Dividend YieldN/A
Average Volume (3M)344.03K
Price to Earnings (P/E)―
Beta (1Y)1.35
Revenue Growth29.37%
EPS Growth-10.38%
CountryAU
Employees96
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.02
Shares Outstanding838,984,740
10 Day Avg. Volume303,620
30 Day Avg. Volume344,030
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)47.09
Price to Sales (P/S)14.39
P/FCF Ratio-20.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.45Price Target Upside73.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$14.80M
Oneview Healthcare Chess Depository Interests repr 1 Business Overview & Revenue Model
Company Description
Oneview Healthcare Chess Depository Interests repr 1 (ONE) is a healthcare technology company that focuses on providing innovative digital solutions to enhance patient and operational outcomes in the healthcare sector. The company primarily offers...
How the Company Makes Money
null...
Oneview Healthcare Chess Depository Interests repr 1 Earnings Call Summary
Earnings Call Date:Feb 11, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Sep 01, 2026
Earnings Call Sentiment Positive
The call communicates strong commercial momentum and meaningful progress on product innovation and AI‑driven productivity—highlighted by 21% reported revenue growth (25%+ constant currency), accelerated deployments, a major Baxter partnership and clear cost‑efficiency gains (H2 OpEx down and >EUR 1.4m annualized run‑rate savings). However, material challenges remain: the company is still operating at an EBITDA loss (EUR 8.1m), cash is modest (EUR 4.6m), gross margin was compressed by revenue mix and conversion of a large Baxter/GPO pipeline and enterprise expansions are uncertain and subject to lengthy sales cycles and regulatory/capital‑spending risks. On balance, the positives (growth, partnerships, product/AI progress and OpEx improvement) outweigh the negatives, but execution and pipeline conversion will be critical to sustain the trajectory.Positive Updates
Strong Revenue Growth
Revenues increased 21% year‑on‑year in 2025 versus 2024 (driven by a EUR 1.6m increase in non‑recurring revenue and 7% growth in annual recurring revenue). On a constant currency basis growth exceeded 25%.
Negative Updates
Ongoing Operating Loss and Cash Position
Operating EBITDA loss reduced by 8% to EUR 8.1m in 2025, but the company remains loss‑making. Cash on hand at 31 Dec 2025 was EUR 4.6m, with cash decline broadly aligned to operating EBITDA loss.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Revenue Growth
Revenues increased 21% year‑on‑year in 2025 versus 2024 (driven by a EUR 1.6m increase in non‑recurring revenue and 7% growth in annual recurring revenue). On a constant currency basis growth exceeded 25%.
Read all positive updates
Company Guidance
The company guided to continued revenue momentum and cost efficiency in 2026, targeting a ~20% increase in endpoints to just under 18,000 (from 14,880 at 31‑Dec‑2025), with H2 deployment activity having accelerated 31% vs H1 and recent contracts averaging ~2.5 endpoints/room; FY‑25 revenues rose 21% (constant currency >25%) driven by a €1.6m increase in non‑recurring revenue and 7% ARR growth, while operating EBITDA loss narrowed 8% to €8.1m, cash at year‑end was €4.6m and inventory €2.9m. Management expects gross margin to remain in the mid‑to‑low 60s (FY‑25: 64%, down 3ppt from mix), and OpEx savings delivered in H2‑25 (run‑rate H1‑25 ≈ €8.4m vs H2 ≈ €7.63m, >€700k half‑year saving, >€1.4m annualized) will be carried into 2026 with further reductions expected later in the year. They reiterated product and commercial levers to drive upside — 18 new logos over the last 3 years representing 11,631 licensed beds and a 46,000‑endpoint addressable set across those logos (~€16m average recurring revenue opportunity), a ~€1.50/day revenue per endpoint benchmark, a 92% upsell rate per bed, inclusion in a Baxter GPO (one of the top 10 U.S. systems) with 156+ qualified Baxter opportunities, and AI/SDLC targets (engineer time savings >15% daily for 76% of the team and a 2026 maturity target of 4/5 for key SDLC phases) supporting faster product delivery and deployments.Oneview Healthcare Chess Depository Interests repr 1 Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.93M | 9.89M | 9.40M | 8.92M | 9.73M |
| Gross Profit | 7.12M | 6.67M | 6.16M | 5.35M | 5.31M |
| EBITDA | -10.48M | -11.26M | -7.88M | -12.09M | -8.01M |
| Net Income | -12.51M | -10.84M | -8.93M | -10.87M | -8.19M |
Balance Sheet | |||||
| Total Assets | 15.49M | 25.96M | 21.92M | 12.75M | 21.09M |
| Cash, Cash Equivalents and Short-Term Investments | 4.60M | 13.83M | 11.55M | 6.41M | 15.18M |
| Total Debt | 1.99M | 1.15M | 935.32K | 543.01K | 1.20M |
| Total Liabilities | 11.84M | 12.71M | 12.78M | 10.50M | 11.19M |
| Stockholders Equity | 3.65M | 13.25M | 9.14M | 2.26M | 9.90M |
Cash Flow | |||||
| Free Cash Flow | -8.38M | -10.52M | -7.79M | -10.24M | -4.09M |
| Operating Cash Flow | -8.32M | -10.47M | -7.26M | -10.20M | -4.03M |
| Investing Cash Flow | -116.31K | -459.78K | -521.38K | -44.52K | -65.26K |
| Financing Cash Flow | -294.26K | 13.14M | 13.04M | -100.11K | 12.22M |
Oneview Healthcare Chess Depository Interests repr 1 Technical Analysis
Neutral
0.26
Price Trends
0.18
Positive
0.24
Negative
0.25
Negative
Market Momentum
>-0.01
Negative
54.10
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ONE, the sentiment is Neutral. The current price of 0.26 is above the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.18, and above the 200-day MA of 0.25, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 54.10 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:ONE.
Oneview Healthcare Chess Depository Interests repr 1 Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$144.43M | 37.28 | 4.37% | ― | 36.43% | ― | |
54 Neutral | AU$49.50M | 22.81 | 250.55% | ― | 1.99% | ― | |
53 Neutral | AU$77.55M | -7.69 | -23.86% | ― | -11.45% | -97.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$138.10M | -6.73 | -226.75% | ― | 29.37% | -10.38% | |
44 Neutral | AU$27.91M | -4.83 | -14.19% | ― | 0.03% | -5.85% | |
40 Underperform | AU$12.75M | -0.21 | -137.16% | ― | -71.80% | -1044.71% |
* Healthcare Sector Average
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.18
-0.09
-32.08%
AU:M7T
Mach7 Technologies
0.33
-0.02
-5.71%
AU:BMT
Beamtree Holdings Ltd
0.10
-0.18
-65.71%
AU:AHE
MedAdvisor Limited
0.02
-0.07
-78.26%
AU:ALC
Alcidion Group Limited
0.11
0.03
33.75%
AU:DOC
Doctor Care Anywhere Group PLC Shs Chess Depository Interests Repr 1 sh
0.14
0.03
28.57%
Oneview Healthcare Chess Depository Interests repr 1 Corporate Events
Oneview Healthcare Reports Lapse of 935,950 Restricted Share Units
May 29, 2026
Oneview Healthcare has announced the cessation of 935,950 restricted share units after the conditions attached to these securities were not met or became incapable of being satisfied as of May 29, 2026. The lapse of these conditional rights reduce...
Oneview Healthcare Adds New ASX-Authorised Representative to Bolster Governance
May 25, 2026
Oneview Healthcare has appointed Claire Stitz, Senior Manager at Computershare Governance Services, as an additional authorised person to liaise with the ASX on Listing Rule matters and to release market announcements on the company’s behalf...
Oneview corrects director interest notice for James Fitter
May 22, 2026
Oneview Healthcare PLC has corrected an error in a previously lodged Director’s Interest Notice for director James Fitter, clarifying the accurate number of CHESS Depositary Interests held following the vesting of Restricted Share Units. The...
Oneview Healthcare Options Lapse, Trimming Potential Future Equity Issuance
May 12, 2026
Oneview Healthcare plc has announced the cessation of 577,250 options (ASX code ONEAE), which lapsed after the conditions attached to these rights were not satisfied or became incapable of being met by 9 May 2026. The lapse reduces the companyR...
Oneview boosts cash reserves and advances AI care platform amid U.S. growth push
Apr 26, 2026
Oneview Healthcare reported a cash balance of €10.3 million at 31 March 2026, boosted by the first tranche of a two-part CHESS Depositary Interests placement that raised A$19 million in gross proceeds. The second tranche, expected to add A$7...
Oneview Healthcare Seeks ASX Quotation for 1.64 Million New CDIs
Apr 16, 2026
Oneview Healthcare has applied for quotation of 1,644,708 new CHESS Depositary Interests on the ASX, on a 1:1 basis, with an issue date of April 17, 2026. The additional securities, issued under a previously announced transaction, will expand the ...
Oneview Delays Share Placement Tranche Two Approval to September AGM
Apr 16, 2026
Oneview Healthcare has updated its plans for the second tranche of a previously announced share placement, clarifying that the proposed issue of securities is contingent on shareholder approval. The company now intends to seek this approval at its...
Oneview Raises A$12.3m as Investor Plan Falls Short of Cap
Apr 16, 2026
Oneview Healthcare has reported the outcome of its security purchase plan, which raised about A$0.3 million through applications for 1,644,708 new CHESS Depositary Interests at A$0.19 each, below the plan’s A$2 million cap, with all valid ap...
Oneview CEO’s Equity Incentives Adjusted as RSUs Vest and Lapse
Apr 15, 2026
Oneview Healthcare has disclosed changes in Chief Executive James Fitter’s equity incentives, reflecting adjustments in his long-term alignment with the company. Fitter acquired 2,000,000 CHESS Depositary Interests (CDIs) through the vesting...
Oneview Healthcare Cancels 3.8 Million Lapsed Restricted Share Units
Apr 14, 2026
Oneview Healthcare PLC has notified the market that 3,815,000 restricted share units, trading under ASX code ONEAF, have lapsed after the conditions for their vesting were not met or became incapable of being satisfied as of April 13, 2026. The ce...
Oneview Healthcare to Quote Nearly 5 Million New CDIs on ASX
Apr 14, 2026
Oneview Healthcare plc, a healthcare technology company listed on the ASX under the code ONE, offers digital solutions that support patient engagement and clinical workflows for hospital and healthcare customers. The company targets providers seek...
Oneview Moves to Close Discounted Security Purchase Plan for Growth and AI Push
Apr 6, 2026
Oneview Healthcare PLC has reminded eligible securityholders that its security purchase plan closes on 10 April 2026, allowing them to subscribe for up to A$30,000 of new CHESS Depositary Interests without transaction costs at A$0.19 per CDI, matc...
Oneview Healthcare launches Security Purchase Plan after A$19m placement
Mar 24, 2026
Oneview Healthcare has opened a Security Purchase Plan for eligible holders of its CHESS Depositary Interests following a A$19 million two-tranche placement to institutional and sophisticated investors. The offer allows eligible investors in Austr...
Oneview Healthcare Completes First Tranche of $19m Capital Raising
Mar 24, 2026
Oneview Healthcare has raised capital through the first tranche of a two-part placement, issuing 63,157,895 new CHESS depository interests at $0.19 each to institutional and sophisticated investors, under its existing 15% placement capacity. The p...
Oneview Healthcare Seeks ASX Quotation for 63 Million New CDIs
Mar 23, 2026
Oneview Healthcare plc has applied to the ASX for quotation of 63,157,895 new CHESS Depositary Interests (CDIs), each representing a 1:1 interest in the underlying securities, with an issue date of March 25, 2026. The additional CDIs, previously f...
Oneview Healthcare Corrects Classification of Prior RSU Issuance Under ASX Rules
Mar 18, 2026
Oneview Healthcare has issued an updated notice to the ASX correcting how a tranche of previously announced restricted share units was classified under the exchange’s listing rules. Of the 15,355,984 RSUs disclosed on 18 March 2025, the comp...
Oneview Healthcare Launches Dual Equity Raising via Placement and SPP
Mar 15, 2026
Oneview Healthcare plans to raise new equity capital through the issue of CHESS Depositary Interests on the ASX via both a placement and a securities purchase plan. The structure targets a maximum of 63,157,895 CDIs under the placement and up to 1...
Oneview Healthcare Plans Major CDI Placement to Raise Capital
Mar 15, 2026
Oneview Healthcare Plc has notified the ASX of a proposed issue of up to 36,842,105 CHESS Depositary Interests on a 1:1 basis as part of a placement or similar capital-raising transaction. The new securities are expected to be issued on 25 May 202...
Oneview Healthcare Raises A$19m in Upsized Placement and Launches SPP to Fund AI and Growth
Mar 15, 2026
Oneview Healthcare has secured commitments for a two‑tranche institutional placement raising A$19 million at A$0.19 per new CDI, with the offer upsized and strongly backed by existing shareholders and new international investors. The company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.